Payment overview · 2025
General Payments
$2,340.05
116 reported records · 26 companies
Healthcare provider profile · identity verified
Cherry Bellosillo Lobaton, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARTINSBURG, WV · NPI 1265467112
Verified facts
What the public records show
CMS Open Payments records show Cherry Bellosillo Lobaton, MD received $2,340.05 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $323.12 | 13.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $270.21 | 11.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $253.57 | 10.8% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $252.62 | 10.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.59 | 9.4% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.42 | 7.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $146.53 | 6.3% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $145.86 | 6.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.76 | 2.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.21 | 2.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.32 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.11 | 1.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.17 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.43 | 1.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.48 | 1.4% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.70 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.45 | 1.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.58 | 1.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.57 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.26 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.17 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.06 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.97 | 0.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $16.67 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.12 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.10 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,340.05 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $252.62 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $210.97 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $178.87 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $175.40 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.40 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $165.08 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $161.87 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $159.40 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $123.17 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $117.74 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.88 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.17 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.99 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.22 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.37 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.55 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $30.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 207 |
| Losartan Potassium | Losartan Potassium | 435 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 69 |
| Lisinopril | Lisinopril | 245 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 66 |
| Omeprazole | Omeprazole | 188 | 62 |
| Gabapentin | Gabapentin | 177 | 55 |
| Metformin Hcl | Metformin Hcl | 165 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 55 |
| Carvedilol | Carvedilol | 151 | 49 |
| Simvastatin | Simvastatin | 144 | 49 |
| Ozempic | Semaglutide | 129 | 29 |
| Meloxicam | Meloxicam | 122 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 41 |
| Alendronate Sodium | Alendronate Sodium | 104 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 32 |
| Allopurinol | Allopurinol | 101 | 30 |
| Trazodone Hcl | Trazodone Hcl | 94 | 35 |
| Alprazolam | Alprazolam | 92 | 18 |
| Sertraline Hcl | Sertraline Hcl | 89 | 27 |
| Eliquis | Apixaban | 83 | 23 |
| Furosemide | Furosemide | 74 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 26 |
| Mounjaro | Tirzepatide | 69 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 66 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 24 |
| Montelukast Sodium | Montelukast Sodium | 61 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 16 |
| Chlorthalidone | Chlorthalidone | 55 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 22 |
| Potassium Chloride | Potassium Chloride | 50 | 17 |
| Tramadol Hcl | Tramadol Hcl | 47 | 14 |
| Atenolol | Atenolol | 44 | 13 |
| Famotidine | Famotidine | 44 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 42 | 14 |
| Donepezil Hcl | Donepezil Hcl | 42 | 16 |
| Clonazepam | Clonazepam | 41 | 13 |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 16 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Glipizide | Glipizide | 30 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | 11 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Baclofen | Baclofen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 17 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,340.05 · 116 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NEXPLANON, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error